Cargando…
Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury
Fasiglifam (TAK-875), a Free Fatty Acid Receptor 1 (FFAR1) agonist in development for the treatment of type 2 diabetes, was voluntarily terminated in phase 3 due to adverse liver effects. A mechanistic investigation described in this manuscript focused on the inhibition of bile acid (BA) transporter...
Autores principales: | Wolenski, Francis S., Zhu, Andy Z. X., Johnson, Mike, Yu, Shaoxia, Moriya, Yuu, Ebihara, Takuya, Csizmadia, Vilmos, Grieves, Jessica, Paton, Martin, Liao, Mingxiang, Gemski, Christopher, Pan, Liping, Vakilynejad, Majid, Dragan, Yvonne P., Chowdhury, Swapan K., Kirby, Patrick J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414857/ https://www.ncbi.nlm.nih.gov/pubmed/28108665 http://dx.doi.org/10.1093/toxsci/kfx018 |
Ejemplares similares
-
Quantitative Systems Toxicology Analysis of In Vitro Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury
por: Longo, Diane M, et al.
Publicado: (2019) -
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1
por: Yabuki, Chiori, et al.
Publicado: (2013) -
Fasiglifam (TAK‐875) has dual potentiating mechanisms via Gαq‐GPR40/FFAR1 signaling branches on glucose‐dependent insulin secretion
por: Sakuma, Kensuke, et al.
Publicado: (2016) -
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus
por: Naik, H, et al.
Publicado: (2013) -
Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPR40) Agonist, May Induce Hepatotoxicity through Reactive Oxygen Species Generation in a GPR40-Dependent Manner
por: Kim, MinJeong, et al.
Publicado: (2018)